Grants4Apps Accelerator 2016: You imagine, Bayer supports

BayerThe Grants4Apps (G4A) Accelerator developed by Bayer invites health IT and technology startups to apply for the program's 2016 edition. This year, Bayer looks primarily into projects aimed at fostering patient-doctor feedback in the Women's Health field as well as those improving patient engagement in Cardiology, Oncology, Radiology and Ophthalmology, but Bayer is also interested in highly innovative software, hardware, technologies applied to digital health fields.

The selected 5 start-ups will get free office space for 100 days at Bayer's Pharmaceuticals headquarters in Berlin, where representatives of Bayer senior management will offer them top-level coaching. In addition, Bayer will provide a financial support of 50,000 Euro to each of the startups.

For the third year in a row, the Grants4Apps Accelerator welcomes startups from around the world, whose software services, technologies, and apps have the potential of creating value for physicians and patients. Projects can be submitted by May 31st, 2016.

"Since 2014, IT and technology passionates from all over the world, with a focus on health projects, are invited to apply for what might become their biggest development opportunity. We are more than proud of the project's echo, especially at a local level, with Bucharest being the 2nd city in overall submissions in 2015. Furthermore, Romania ranked 6th in terms of number of submissions received from all over the world, which is outstanding. We are confident that the 2016 edition will suscitate at least as much interest and local bright ideas will improve people's lives," said Ruxandra Pirojoc, Head of Communications for Bayer Romania and Bulgaria.

"At Bayer, we strongly believe in the power of the local community - Scientists, Technologists, Engineers, and Mathematicians in Bucharest, working or willing to work on projects regarding digital health and digital farming. This is why we have established a group on meetup.com, aimed at fostering innitiave and cooperation between professionals, while also serving as a networking and discussions platform. It is a local innitiave matching Bayer’s vision of open innovation and global cooperation," added George Nancu, IT Specialist at Bayer Romania.

In June, an expert jury from Bayer will select the five winners who will be invited to spend 3.5 months in the Accelerator on the Bayer Pharmaceuticals headquarters in Berlin from August to December 2016. Aside from the financial support to help developing their business, the startups will be offered free co-working space, mentoring and expert advice on business development, market research, financial planning, and pitching for investors. The goal for the startups in the program is to further develop their product and business model so they can obtain financing from other sources after the program.

Application forms for startups are available at the Grants4Apps website http://www.grants4apps.com/berlin

Bayer fully embraces new approaches of open innovation, such as the "CoLaborator" or crowdsourcing initiatives like "Grants4Targets", "Grants4Indications", "Grants4Apps" and "PartnerYourAntibodies".

Bayer: Science for a Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...

Addressing social and cultural drivers of type 2 d…

New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffective, unless they address social and ...

Evidence mounts linking aspirin to lower risk of o…

Taking a low-dose aspirin daily may help women lower their risk of developing ovarian cancer. A new study co-led by Moffitt Cancer Center found that women who reported ta...